Supplementary Tables 1-5 from Considerations for the Clinical Application of Chimeric Antigen Receptor T Cells: Observations from a <i>Recombinant DNA Advisory Committee Symposium</i> Held June 15, 2010
Hildegund C.J. Ertl(The Wistar Institute), Scott E. Strome(Northwestern Medicine Lake Forest Hospital), Gianpietro Dotti(University of North Carolina at Chapel Hill), Laurence J.N. Cooper(The University of Texas MD Anderson Cancer Center), Steven A. Rosenberg(National Cancer Institute), Jacqueline Corrigan‐Curay(National Institutes of Health), John A. Zaia(City Of Hope National Medical Center), Jeffrey Kahn(University of Maryland, Baltimore), Carl H. June(University of Pennsylvania)
Cited by 0
Related Papers
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion
|Nature Medicine|2002|5.1k
A human memory T cell subset with stem cell–like properties
|Nature Medicine|2011|2k
Adoptive Cell Therapy for Patients With Metastatic Melanoma: Evaluation of Intensive Myeloablative Chemoradiation Preparative Regimens
|Journal of Clinical Oncology|2008|1.3k
IL-2: The First Effective Immunotherapy for Human Cancer
|The Journal of Immunology|2014|1.3k